Michela Buglione
Overview
Explore the profile of Michela Buglione including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1306
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Guerini A, Noale M, Mortellaro G, Lisi R, Bruni A, Santini R, et al.
Front Oncol
. 2022 Nov;
12:951220.
PMID: 36408148
Although radiotherapy plays a fundamental role in the management of intermediate/high/very high-risk non-metastatic prostatic cancer (IHR-nmPca), there is still no consensus on the optimal treatment strategy in this setting. Remarkably,...
12.
Bonu M, La Mattina S, Singh N, Toraci C, Spiazzi L, Terraneo F, et al.
Front Oncol
. 2022 Nov;
12:973223.
PMID: 36353538
Introduction: Radiochemotherapy (RCHT) for the treatment of anal squamous cell carcinoma (ASCC) has evolved dramatically, also thanks to intensity-modulated RT (IMRT) and 3D image guidance (3D IGRT). Despite most patients...
13.
Magrini S, Tomasini D, Foca E, Garrafa E, Singh N, Guerini A, et al.
In Vivo
. 2022 Jun;
36(4):1959-1965.
PMID: 35738608
Aim: To evaluate the feasibility and tolerability of low-dose radiotherapy (LDRT) delivered to both lungs in the treatment of SARS-CoV-2-immune-mediated pneumonia in the COLOR-19 study (NCT0437747). Patients And Methods: From...
14.
Guerini A, Tucci A, Alongi F, Mataj E, Belotti A, Borghetti P, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565401
Background and purpose: Although chemotherapy, biological agents, and radiotherapy (RT) are cornerstones of the treatment of multiple myeloma (MM), the literature regarding the possible interactions of concurrent systemic treatment (CST)...
15.
Buglione M, Alterio D, Maddalo M, Greco D, Gerardi M, Tomasini D, et al.
Radiat Oncol
. 2021 Dec;
16(1):239.
PMID: 34930353
Background: Radio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m/q3 is the standard; alternative schedules are used to reduce toxicity, mostly 40 mg/m/q1. Methods: Patients...
16.
Bossi P, Trama A, Bernasconi A, Grisanti S, Mohamad I, Galiana I, et al.
Eur J Cancer
. 2021 Nov;
159:194-204.
PMID: 34773903
Aim: Recommendations for managing patients with nasopharyngeal carcinoma (NPC) in non-endemic areas are largely derived from studies conducted in endemic areas. We analysed the impact of treatment approaches on survival...
17.
Guerini A, Filippi A, Tucci A, Simontacchi G, Re A, Guaineri A, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Nov;
22(2):e135-e148.
PMID: 34728169
Background: immunotherapy (IT), including checkpoint inhibitors (CIs) and Chimeric Antigen Receptor T cell therapy (CAR-T) revolutionized the treatment of relapsing or refractory (r/r) lymphoma. Several preliminary experiences evaluated concomitant administration...
18.
Ricardi U, Levis M, Evangelista A, Gioia D, Sacchetti G, Gotti M, et al.
Blood Adv
. 2021 Oct;
5(21):4504-4514.
PMID: 34597375
The role of consolidation radiotherapy (RT) for bulky lesions is controversial in patients with advanced-stage Hodgkin lymphoma who achieve complete metabolic response (CMR) after doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)-based chemotherapy....
19.
Magrini S, Guerini A, Borghetti P, Volpi G, Triggiani L, Costa L, et al.
Tumori
. 2021 Aug;
108(3):278-282.
PMID: 34405756
Background: The impact of coronavirus disease 2019 (COVID-19) has been overwhelming on patients with cancer, who may be at higher risk of developing severe disease. During the second COVID-19 outbreak...
20.
Buglione M, Guerini A, Filippi A, Spiazzi L, Pasinetti N, Magli A, et al.
Crit Rev Oncol Hematol
. 2021 Aug;
167:103437.
PMID: 34358649
Background: Secondary malignant neoplasms (SMNs) and cardiovascular diseases induced by chemotherapy and radiotherapy represent the main cause of excess mortality for early-stage Hodgkin lymphoma patients, especially when the mediastinum is...